“Laboratory Parameters in Adolescent Patients Aged 12–17 with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial” (2024) SKIN The Journal of Cutaneous Medicine, 8(1), p. s323. doi:10.25251/skin.8.supp.323.